These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8453319)

  • 61. Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers.
    Kok DJ; Papapoulos SE; Bijvoet OL
    Contrib Nephrol; 1987; 58():73-7. PubMed ID: 3691150
    [No Abstract]   [Full Text] [Related]  

  • 62. [Clinical studies of the recurrence of urolithiasis (4). Crystal formation in urine and stone recurrence].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1988 Sep; 34(9):1543-7. PubMed ID: 3213790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis.
    Dey J; Creighton A; Lindberg JS; Fuselier HA; Kok DJ; Cole FE; Hamm L
    J Urol; 2002 Jan; 167(1):169-71. PubMed ID: 11743298
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hydroxyapatite induction and secondary aggregation of calcium oxalate, two important processes in calcium stone formation.
    Baumann JM; Affolter B; Caprez U; Henze U; Lauper D; Maier F
    Urol Res; 2001 Dec; 29(6):417-22. PubMed ID: 11828996
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens.
    Ogawa Y; Yonou H; Hokama S; Oda M; Morozumi M; Sugaya K
    Front Biosci; 2003 Sep; 8():a167-76. PubMed ID: 12957883
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patients Attending Shared Medical Appointments for Metabolic Stone Prevention Have Decreased Stone Risk Factors.
    Jhagroo RA; Nakada SY; Penniston KL
    J Endourol; 2016 Nov; 30(11):1262-1268. PubMed ID: 27673722
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibitors of calcium oxalate crystallization and urolithiasis.
    Grases F; Conte A; Genestar C; Costa-Bauzá A
    Urol Int; 1992; 48(4):409-14. PubMed ID: 1413303
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Urinary Tamm-Horsfall protein increased after potassium citrate therapy in calcium stone formers.
    Fuselier HA; Ward DM; Lindberg JS; Allen JM; Husserl FE; Marcucci PA; Cole FE; Turnipseed J; Alam J; Kok DJ
    Urology; 1995 Jun; 45(6):942-6. PubMed ID: 7771027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk factors for urinary calcium oxalate crystals as revealed by their specific enzymatic assay.
    Hallson PC; Rose GA
    Br J Urol; 1989 Nov; 64(5):451-7. PubMed ID: 2611612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Hyperuricosuria and urolithiasis].
    Koide T
    Nihon Rinsho; 1996 Dec; 54(12):3273-6. PubMed ID: 8976104
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Granulated potassium citrate in the prevention of calcium oxalate lithiasis].
    Campoy Martínez P; Arrabal Martín M; Quintero Rodríguez R; Espinosa Olmedo FJ; Castillo Gómez J; García Pérez M
    Actas Urol Esp; 1994 Feb; 18(2):101-5. PubMed ID: 7976691
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former.
    Hess B; Jordi S; Zipperle L; Ettinger E; Giovanoli R
    Nephrol Dial Transplant; 2000 Mar; 15(3):366-74. PubMed ID: 10692522
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is there a role for pentosan polysulfate in the prevention of calcium oxalate stones?
    Jones M; Monga M
    J Endourol; 2003 Dec; 17(10):855-8. PubMed ID: 14744348
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment.
    Lewandowski S; Rodgers AL
    Clin Chim Acta; 2004 Jul; 345(1-2):17-34. PubMed ID: 15193974
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
    Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
    J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does urinary oxalate interfere with the inhibitory role of glycosaminoglycans and semisynthetic sulfated polysaccharides in calcium oxalate crystallization?
    Cao LC; Deng G; Boevé ER; Romijn JC; de Bruijn WC; Verkoelen CF; Schröder FH
    Eur Urol; 1997; 31(4):485-92. PubMed ID: 9187912
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial.
    Allie-Hamdulay S; Rodgers AL
    Urol Res; 2005 May; 33(2):116-24. PubMed ID: 15871014
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial.
    Soygür T; Akbay A; Küpeli S
    J Endourol; 2002 Apr; 16(3):149-52. PubMed ID: 12028622
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts.
    Sakhaee K; Nicar M; Hill K; Pak CY
    Kidney Int; 1983 Sep; 24(3):348-52. PubMed ID: 6645208
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative study of the effects of pyruvate and CG-120 in preventing experimental oxalate urolithiasis in rats.
    Ogawa Y; Yamaguchi K; Tanaka T; Morozumi M
    Hinyokika Kiyo; 1986 Sep; 32(9):1341-7. PubMed ID: 3812152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.